Citigroup
JANX icon

Citigroup’s Janux Therapeutics JANX Stock Holding History

Citigroup’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07K Buy
+200
New +$2.9K ﹤0.01% 5353
2025
Q3 		– Sell
-30,000
Closed -$693K – 6208
2025
Q2 		$693K Buy
30,000
+15,000
+100% +$395K ﹤0.01% 3416
2025
Q1 		$405K Sell
15,000
-15,000
-50% -$565K ﹤0.01% 3787
2024
Q4 		$1.61M Buy
+30,000
New +$1.59M ﹤0.01% 2981

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Citigroup's JANX Position: Q2 2026 in Review

Citigroup increased its Janux Therapeutics (JANX) stake by 498% in Q2 2026, buying an estimated $847K and bringing the position to 70,235 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #3396.

Citigroup first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $4.26M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Citigroup held 70,235 shares of Janux Therapeutics worth $1.08M as of Q2 2026.
  • Citigroup bought 58,497 Janux Therapeutics shares in Q2 2026, an estimated $847K.
  • Janux Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3396 holding.
  • Citigroup first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Citigroup's Janux Therapeutics position peaked at $4.26M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.